Stifel starts Zyus Life Sciences with a Speculative Buy rating, C$4 price target

As previously reported last night, Stifel initiated coverage of Zyus Life Sciences with a Speculative Buy rating and C$4 price target. Founder, President and CEO Brent Zettl has been pursuing drug commercialization using a cannabinoid formulation for 23 years and his previous endeavor culminated in “the largest takeover in the cannabis industry at the time,” notes the analyst. The firm believes Zyus’ lead drug candidate, Trichomylin, is “well positioned to offer investors an attractive risk/ reward opportunity” with a successful Phase 1 already completed and multiple data points suggesting efficacy, the analyst added.